Market Research Life Sciences Market Research Pharmaceuticals Market Research Drug Discovery Market Research

Asia-pacific Alzheimer’s Disease Therapeutics And Diagnostics Market 2022-2028

Best Price Guarantee Length Publisher Published Date SKU
from $1,500 125 Pages Triton Market Research August, 2022 TRTN17344015
Best Price Guarantee
Price from $1,500
Length 125 Pages
Publisher Triton Market Research
Published Date August, 2022
SKU TRTN17344015

Asia-pacific Alzheimer’s Disease Therapeutics And Diagnostics Market 2022-2028

MARKET OUTLOOK

A Triton Market Research report states that the Alzheimer’s disease therapeutics and diagnostics market in the Asia-Pacific would fast progress with a CAGR of 12.18% over the forecast duration from 2022 to 2028. Japan, India, South Korea, China, Australia & New Zealand, ASEAN countries, and Rest of Asia-Pacific are assessed in the market in this region.

South Korea’s population is aging rapidly. The number of people aged 65 years or above is predicted to reach 12.658 million (24.7%) by 2030, as per the World Population Ageing 2019 study. Due to the rising elderly population’s increased susceptibility to neurological illnesses, including Alzheimer’s disease, the demand for its therapeutics and diagnostics is expected to surge. As a result, the Alzheimer’s disease therapeutics and diagnostics market in the country is anticipated to experience growth during the forecast period.

The Japanese market for Alzheimer’s disease diagnostics and therapeutics is also anticipated to grow favorably over the forecast period, thanks to a strong healthcare system to meet the demands of the rapidly growing geriatric population suffering from dementia, as well as effective public policies and dedicated research for introducing novel treatments. R&D activities for Alzheimer’s detection are in full swing, as the overall understanding of the disease pathology has also gained significant momentum in the last few years. The National Clinical Trials Registry (NCT) reports that, there are roughly 15 ongoing clinical trials for Alzheimer’s disease across various phases at present, in the country. Such developments are expected to foster the market’s growth.

COMPETITIVE OUTLOOK

The prominent companies in the Alzheimer’s disease therapeutics and diagnostics market are Cognoptix Inc, Eli Lilly & Company, Novartis AG, GE Healthcare, Pfizer Inc, Eisai Co Ltd, F. Hoffmann-La Roche AG, Baxter International Inc, and Sun Pharmaceuticals Industries Ltd.


1. Asia-pacific Alzheimer’s Disease Therapeutics And Diagnostics Market – Summary
2. Industry Outlook
2.1. Timeline Of Alzheimer’s Disease Therapeutics And Diagnostics Market
2.2. Phases And Sternness Of Alzheimer’s Disease
2.3. Key Insights
2.3.1. Usage Of Computed Tomography For The Diagnosis Of Alzheimer’s Disease
2.3.2. R&D Investments In Biomarkers For Early Detection Of Dementia
2.3.3. Demand For Personalized Medicines
2.4. Impact Of Covid-19 On The Alzheimer’s Disease Therapeutics And Diagnostics Market
2.5. Porter’s Five Forces Analysis
2.6. Market Attractiveness Matrix
2.7. Vendor Scorecard
2.8. Industry Components
2.8.1. Research & Development (R & D)
2.8.2. Raw Materials
2.8.3. Manufacturing
2.8.4. Distributors/Wholesalers/Retailers
2.8.5. End-user
2.9. Key Impact Analysis
2.9.1. Effectiveness
2.9.2. Price
2.9.3. Safety
2.10. Key Market Strategies
2.10.1. Acquisitions
2.10.2. Product Launches
2.10.3. Contracts & Agreements
2.10.4. Investments & Expansions
2.11. Market Drivers
2.11.1. Prevalence Of Alzheimer’s Disease
2.11.2. Rise In The Elderly Population
2.12. Market Challenges
2.12.1. Failure Of Late-stage Drugs
2.12.2. Stringent Government Regulations
2.13. Market Opportunities
2.13.1. Emergence Of New Diagnostic Technologies
2.13.2. Growing Number Of Pipeline Drugs
3. Asia-pacific Alzheimer’s Disease Therapeutics And Diagnostics Market – By Therapeutics
3.1. By Drug Type
3.1.1. Marketed Drugs
3.1.2. Pipeline Drugs
3.2. By Disease Stage
3.2.1. Late Stage: Severe Ad
3.2.2. Early/Middle Stage: Mild To Moderate Ad
3.2.3. Prodromal Stage
3.3. By Generic & Branded
3.3.1. Branded
3.3.2. Generic
4. Asia-pacific Alzheimer’s Disease Therapeutics And Diagnostics Market – By Diagnostics
4.1. Lumbar Puncture Test
4.2. Positron Emission Tomography
4.3. Electroencephalography
4.4. Magnetic Resonance Imaging
4.5. Computed Tomography
4.6. Blood Test
4.7. Other Diagnostics
5. Asia-pacific Alzheimer’s Disease Therapeutics And Diagnostics Market – Country Outlook
5.1. China
5.2. Japan
5.3. India
5.4. South Korea
5.5. Asean Countries
5.6. Australia And New Zealand
5.7. Rest Of Asia-pacific
6. Competitive Landscape
6.1. Baxter International Inc
6.2. F. Hoffmann-la Roche Ag
6.3. Allergan Plc (Acquired By Abbvie)
6.4. Novartis Ag
6.5. Pfizer Inc
6.6. Siemens Healthineers Ag
6.7. Amarantus Bioscience Holdings Inc
6.8. Eisai Co Ltd
6.9. Eli Lilly & Company
6.10. Lupin Limited
6.11. Merck And Co
6.12. Biogen Inc
6.13. Cognoptix Inc
6.14. Ge Healthcare
6.15. Johnson And Johnson
6.16. Sun Pharmaceuticals Industries Ltd
6.17. Teva Pharmaceutical Industries Ltd
6.18. Zydus Cadila
7. Methodology & Scope
7.1. Research Scope
7.2. Sources Of Data
7.3. Research Methodology
Table List
Table 1: Asia-pacific Alzheimer’s Disease Therapeutics And Diagnostics Market, Country Outlook, 2022-2028 (In $ Million)
Table 2: Market Attractiveness Matrix
Table 3: Vendor Scorecard
Table 4: Key Strategic Developments
Table 5: Asia-pacific Alzheimer’s Disease Therapeutics And Diagnostics Market, By Therapeutics, 2022-2028 (In $ Million)
Table 6: Asia-pacific Alzheimer’s Disease Therapeutics Market, By Drug Type, 2022-2028 (In $ Million)
Table 7: Asia-pacific Alzheimer’s Disease Therapeutics Market, By Disease Stage, 2022-2028 (In $ Million)
Table 8: Asia-pacific Alzheimer’s Disease Therapeutics Market, By Generic & Branded, 2022-2028 (In $ Million)
Table 9: Asia-pacific Alzheimer’s Disease Therapeutics And Diagnostics Market, By Diagnostics, 2022-2028 (In $ Million)
Table 10: Asia-pacific Alzheimer’s Disease Therapeutics And Diagnostics Market, Country Outlook, 2022-2028 (In $ Million)
Figure List
Figure 1: Porter’s Five Forces Analysis
Figure 2: Key Impact Analysis
Figure 3: Timeline Of Alzheimer’s Disease Therapeutics And Diagnostics
Figure 4: Industry Components
Figure 5: Asia-pacific Alzheimer’s Disease Therapeutics And Diagnostics Market, By Therapeutics, 2021 & 2028 (In %)
Figure 6: Asia-pacific Alzheimer’s Disease Therapeutics Market, By Drug Type, 2021 & 2028 (In %)
Figure 7: Asia-pacific Alzheimer’s Disease Therapeutics Market, By Marketed Drugs, 2022-2028 (In $ Million)
Figure 8: Asia-pacific Alzheimer’s Disease Therapeutics Market, By Pipeline Drugs, 2022-2028 (In $ Million)
Figure 9: Asia-pacific Alzheimer’s Disease Therapeutics Market, By Disease Stage, 2021 & 2028 (In %)
Figure 10: Asia-pacific Alzheimer’s Disease Therapeutics Market, By Late Stage: Severe Ad, 2022-2028 (In $ Million)
Figure 11: Asia-pacific Alzheimer’s Disease Therapeutics Market, By Early/Middle Stage: Mild To Moderate Ad, 2022-2028 (In $ Million)
Figure 12: Asia-pacific Alzheimer’s Disease Therapeutics Market, By Prodromal Stage, 2022-2028 (In $ Million)
Figure 13: Asia-pacific Alzheimer’s Disease Therapeutics Market, By Generic & Branded, 2021 & 2028 (In %)
Figure 14: Asia-pacific Alzheimer’s Disease Therapeutics Market, By Branded, 2022-2028 (In $ Million)
Figure 15: Asia-pacific Alzheimer’s Disease Therapeutics Market, By Generic, 2022-2028 (In $ Million)
Figure 16: Asia-pacific Alzheimer’s Disease Therapeutics And Diagnostics Market, By Diagnostics, 2021 & 2028 (In %)
Figure 17: Asia-pacific Alzheimer’s Disease Diagnostics Market, By Lumbar Puncture Test, 2022-2028 (In $ Million)
Figure 18: Asia-pacific Alzheimer’s Disease Diagnostics Market, By Positron Emission Tomography, 2022-2028 (In $ Million)
Figure 19: Asia-pacific Alzheimer’s Disease Diagnostics Market, By Electroencephalography, 2022-2028 (In $ Million)
Figure 20: Asia-pacific Alzheimer’s Disease Diagnostics Market, By Magnetic Resonance Imaging, 2022-2028 (In $ Million)
Figure 21: Asia-pacific Alzheimer’s Disease Diagnostics Market, By Computed Tomography, 2022-2028 (In $ Million)
Figure 22: Asia-pacific Alzheimer’s Disease Diagnostics Market, By Blood Test, 2022-2028 (In $ Million)
Figure 23: Asia-pacific Alzheimer’s Disease Diagnostics Market, By Other Diagnostics, 2022-2028 (In $ Million)
Figure 24: Asia-pacific Alzheimer’s Disease Therapeutics And Diagnostics Market, Country Outlook, 2021 & 2028 (In %)
Figure 25: China Alzheimer’s Disease Therapeutics And Diagnostics Market, 2022-2028 (In $ Million)
Figure 26: Japan Alzheimer’s Disease Therapeutics And Diagnostics Market, 2022-2028 (In $ Million)
Figure 27: India Alzheimer’s Disease Therapeutics And Diagnostics Market, 2022-2028 (In $ Million)
Figure 28: South Korea Alzheimer’s Disease Therapeutics And Diagnostics Market, 2022-2028 (In $ Million)
Figure 29: Asean Countries Alzheimer’s Disease Therapeutics And Diagnostics Market, 2022-2028 (In $ Million)
Figure 30: Australia & New Zealand Alzheimer’s Disease Therapeutics And Diagnostics Market, 2022-2028 (In $ Million)
Figure 31: Rest Of Asia-pacific Alzheimer’s Disease Therapeutics And Diagnostics Market, 2022-2028 (In $ Million)

$1,500
$2,200

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings